FY2024 Earnings Estimate for Design Therapeutics, Inc. (NASDAQ:DSGN) Issued By Leerink Partnrs

Design Therapeutics, Inc. (NASDAQ:DSGN) – Equities research analysts at Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for Design Therapeutics in a research note issued to investors on Monday, August 5th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($0.87) per share for the year, up from their previous forecast of ($0.89). The consensus estimate for Design Therapeutics’ current full-year earnings is ($1.02) per share. Leerink Partnrs also issued estimates for Design Therapeutics’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.96) EPS and FY2026 earnings at ($1.13) EPS.

Design Therapeutics (NASDAQ:DSGN) last released its earnings results on Monday, August 5th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02.

DSGN has been the subject of several other research reports. Piper Sandler raised shares of Design Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $6.00 to $12.00 in a research report on Tuesday, May 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price objective on shares of Design Therapeutics in a research report on Tuesday. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.60.

Design Therapeutics Trading Up 4.4 %

NASDAQ:DSGN traded up $0.18 on Thursday, reaching $4.24. 921,323 shares of the stock traded hands, compared to its average volume of 242,688. The firm has a market capitalization of $239.54 million, a price-to-earnings ratio of -4.04 and a beta of 1.83. The company’s 50 day moving average is $4.00 and its 200-day moving average is $3.57. Design Therapeutics has a 1-year low of $1.94 and a 1-year high of $7.83.

Institutional Trading of Design Therapeutics

Hedge funds have recently bought and sold shares of the company. Pale Fire Capital SE bought a new stake in Design Therapeutics in the 4th quarter worth approximately $28,000. Nisa Investment Advisors LLC lifted its position in Design Therapeutics by 38,433.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 11,560 shares of the company’s stock worth $31,000 after buying an additional 11,530 shares during the last quarter. Federated Hermes Inc. lifted its position in Design Therapeutics by 317.6% in the 4th quarter. Federated Hermes Inc. now owns 11,999 shares of the company’s stock worth $32,000 after buying an additional 9,126 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Design Therapeutics in the first quarter valued at approximately $45,000. Finally, Simplicity Wealth LLC bought a new stake in Design Therapeutics in the first quarter valued at approximately $46,000. Institutional investors own 56.64% of the company’s stock.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.